Literature DB >> 23054210

Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells.

Amna Ali1, Tatyana S Sidorova, Diane F Matesic.   

Abstract

Chaetoglobosin K (ChK) is a natural product that inhibits anchorage-dependent and anchorage-independent growth of ras-transformed cells, prevents tumor-promoter disruption of cell-cell communication, and reduces Akt activation in tumorigenic cells. This study demonstrates how ChK modulates the JNK pathway in ras-transformed and human lung carcinoma cells and investigates regulatory mechanisms controlling ChK's effect on the Akt and JNK signaling pathways. Human lung carcinoma and ras-transformed epithelial cell lines treated with ChK or vehicle for varying times were assayed for cell growth or extracted for total proteins for western blot analysis using phosphorylation site-specific antibodies to monitor changes in activation of JNK, Akt, and other signaling enzymes. Results show that ChK inhibited both Akt and JNK phosphorylation at key activation sites in ras-transformed cells as well as human lung carcinoma cells. Downstream effectors of both kinases were accordingly affected. Direct upstream kinases of JNK were not affected by ChK. Wortmannin and LY294002, two PI3 kinase inhibitors, inhibited Akt but not JNK phosphorylation in ras-transformed cells. This report establishes the dual inhibitory effect of ChK on both the Akt and JNK signaling pathways in ras-transformed epithelial and human carcinoma cells. The unique effect of ChK on these two key pathways involved in carcinogenesis earmarks ChK for further studies to determine its molecular target(s) and in vivo anti-tumor potential.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054210      PMCID: PMC3915520          DOI: 10.1007/s10637-012-9883-x

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  41 in total

Review 1.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

Review 2.  The JAK/STAT signaling pathway.

Authors:  Jason S Rawlings; Kristin M Rosler; Douglas A Harrison
Journal:  J Cell Sci       Date:  2004-03-15       Impact factor: 5.285

3.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

Authors:  Shazli N Malik; Michael Brattain; Paramita M Ghosh; Dean A Troyer; Thomas Prihoda; Roble Bedolla; Jeffrey I Kreisberg
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

4.  Elevated JNK activation contributes to the pathogenesis of human brain tumors.

Authors:  Marc A Antonyak; Lawrence C Kenyon; Andrew K Godwin; David C James; David R Emlet; Isamu Okamoto; Mehdi Tnani; Marina Holgado-Madruga; David K Moscatello; Albert J Wong
Journal:  Oncogene       Date:  2002-08-01       Impact factor: 9.867

5.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

6.  Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Authors:  Meenakshi Jain; Constadina Arvanitis; Kenneth Chu; William Dewey; Edith Leonhardt; Maxine Trinh; Christopher D Sundberg; J Michael Bishop; Dean W Felsher
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

7.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

8.  Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

Authors:  Lin Yang; Han C Dan; Mei Sun; Qiyuan Liu; Xia-meng Sun; Richard I Feldman; Andrew D Hamilton; Mark Polokoff; Santo V Nicosia; Meenhard Herlyn; Said M Sebti; Jin Q Cheng
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

9.  Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.

Authors:  Jeffrey I Kreisberg; Shazli N Malik; Thomas J Prihoda; Roble G Bedolla; Dean A Troyer; Suzanne Kreisberg; Paramita M Ghosh
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 10.  Stress-activated protein kinases-tumor suppressors or tumor initiators?

Authors:  David Engelberg
Journal:  Semin Cancer Biol       Date:  2004-08       Impact factor: 15.707

View more
  6 in total

1.  A Cell-Cell Communication Marker for Identifying Targeted Tumor Therapies.

Authors:  Diane F Matesic; Amna Ali; Tatyana S Sidorova; Timothy J Burns
Journal:  Curr Bioact Compd       Date:  2013

2.  Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells.

Authors:  Blair P Curless; Nne E Uko; Diane F Matesic
Journal:  Invest New Drugs       Date:  2018-12-13       Impact factor: 3.850

3.  Progress in the Chemistry of Cytochalasans.

Authors:  Hucheng Zhu; Chunmei Chen; Qingyi Tong; Yuan Zhou; Ying Ye; Lianghu Gu; Yonghui Zhang
Journal:  Prog Chem Org Nat Prod       Date:  2021

4.  Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1α.

Authors:  Haitao Luo; Bingyun Li; Zhaoliang Li; Stephen J Cutler; Gary O Rankin; Yi C Chen
Journal:  Anticancer Drugs       Date:  2013-08       Impact factor: 2.248

5.  Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatin-resistant ovarian cancer cells.

Authors:  Bo Li; Ying Gao; Gary O Rankin; Yon Rojanasakul; Stephen J Cutler; Youying Tu; Yi Charlie Chen
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

6.  Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer.

Authors:  So-Young Seol; Chul Kim; Jae Yun Lim; Sun Och Yoon; Soon Won Hong; Jong Won Kim; Seung Ho Choi; Jae Yong Cho
Journal:  Cancer Res Treat       Date:  2016-02-26       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.